We analyzed the levels of hormones stratified by mortality in the patients that had critical COVID-19 and found that TMPRSS2 (4.3 ± 0.59 vs. 2.3 ± 0.4 ng/mL, p < 0.01), estradiol (81 ± 13.7 vs. 43 ± 10.6 pg/mL, p = 0.05) and aromatase (9.3 ± 0.74 vs. 6.4 ± 0.3 ng/mL, p < 0.01) were significantly higher in non-survivors. This evidence concerns the gene CYP19A1 and COVID-19.